SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ferlay J,Bray F,Pisani P,Parkin D. Cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC CancerBase, 5th ed. Lyon, France: IARC Press; 2000.
  • 2
    Aus G,Abbou CC,Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2005; 48: 546551.
  • 3
    Manoharran M,Bird VG,Kim SS,Civantos F,Soloway MS. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥8. BJU Int. 2003; 92: 539544.
  • 4
    Antenor JAV,Roehl KA,Eggener SE,Kundu SD,Han M,Catalona WJ. Preoperative PSA and progression-free survival after radical prostatectomy for stage T1c disease. Urology. 2005; 66: 156116.
  • 5
    Fall K,Garmo H,Bill-Axelsson A, et al.; Scandinavian Prostate Cancer Group Study No. 4. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007; 99: 526532.
  • 6
    Albertsen PC,Hanley JA,Gleason DF,Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localised prostate cancer. JAMA. 1998; 280: 975980.
  • 7
    Shekarriz B,Upadhyay J,Bianco FJJr, et al. Impact of preoperative serum PSA level from 0 to 10 ng/mL on pathological findings and disease-free survival after radical prostatectomy. Prostate. 2001; 48: 136143.
  • 8
    Thompson IM,Pauler DK,Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004; 350: 22392246.
  • 9
    Krumholts JS,Carvalhal GF,Ramos CG, et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favourable pathological tumor features. Urology. 2002; 60: 469474.
  • 10
    Jang TL,Han M,Roehl KA,Hawkins SA,Catalona WJ. More favourable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology. 2006; 67: 343348.
  • 11
    Thompson IM,Ankerst DP,Chi C, et al. Operating characteristics of prostate specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA. 2005; 294: 6670.
  • 12
    Mattson B. The completeness of registration in the Swedish Cancer Registry. Statistical report no. 15. Stockholm, Sweden: Swedish Board of Health and Welfare; 1977.
  • 13
    Stattin P,Johansson R,Lodnert R, et al. Geographical variation in incidence of prostate cancer in Sweden. Scan J Urol Nephrol. 2005; 39: 372379.
  • 14
    Varenhorst E,Garmo H,Holmberg L, et al. The National Prostate Cancer Register in Sweden 1998–2002: trends in incidence, treatment and survival. Scand J Urol Nephrol. 2005; 39: 117123.
  • 15
    SobinLH,WittekindC, eds. TNM classification of malignant tumors,6th ed. New York, NY: John Wiley & Sons; 2002.
  • 16
    Sweden's Statistical Databases. Available at URL: http://www.ssd.scb.se. Accessed December 11, 2007.
  • 17
    Gronberg H,Damber L,Jonson H,Damber JE. Prostate cancer mortality in Northern Sweden, with special reference to tumor grade and patient age. Urology. 1997; 49: 374378.
  • 18
    Partin AW,Carter HB,Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990; 143: 747752.
  • 19
    Yamamoto S,Ito T,Akiyama A,Aizawa T,Miki M,Tachibana M. M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL. Int J Urol. 2001; 8: 374379.